BioCentury
ARTICLE | Distillery Therapeutics

Therapeutics: Myeloperoxidase (MPO)

April 16, 2015 7:00 AM UTC

In vitro and mouse studies suggest the MPO inhibitor PF-1355 could help prevent or treat vasculitis. In human neutrophil- and blood-based assays, the 2-thiouracil-based compound PF-1355 inhibited MPO activity with EC50 values of 1.6 and 2.0 μM, respectively. In a mouse model of renal vasculitis, pretreatment with PF-1355 decreased acute and chronic renal dysfunction compared with vehicle pretreatment. In a mouse model of pulmonary vasculitis, PF-1355 decreased vascular edema and pulmonary levels of infiltrating immune cells and pro-inflammatory cytokines compared with vehicle. Next steps by Pfizer Inc. could include testing PF-1355's activity in additional models of vasculitis...